Pamela Provan

457 total citations
18 papers, 261 citations indexed

About

Pamela Provan is a scholar working on Genetics, Cancer Research and Oncology. According to data from OpenAlex, Pamela Provan has authored 18 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Pamela Provan's work include BRCA gene mutations in cancer (4 papers), Estrogen and related hormone effects (4 papers) and Breast Cancer Treatment Studies (4 papers). Pamela Provan is often cited by papers focused on BRCA gene mutations in cancer (4 papers), Estrogen and related hormone effects (4 papers) and Breast Cancer Treatment Studies (4 papers). Pamela Provan collaborates with scholars based in Australia, United States and Brazil. Pamela Provan's co-authors include Rosemary L. Balleine, Karen Byth, Nirmala Pathmanathan, A. Michael Bilous, Elizabeth Salisbury, Christopher Liddle, Peter Fox, Upali W Jayasinghe, Rina Hui and John Boyages and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Medical Internet Research.

In The Last Decade

Pamela Provan

17 papers receiving 256 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pamela Provan Australia	10	120	109	82	75	66	18	261
Bryony Eccles United Kingdom	8	174 1.4×	236 2.2×	115 1.4×	61 0.8×	36 0.5×	11	363
Kylea Potvin Canada	10	84 0.7×	154 1.4×	91 1.1×	120 1.6×	24 0.4×	28	341
Lynn Jongen Belgium	7	99 0.8×	132 1.2×	105 1.3×	29 0.4×	21 0.3×	13	237
F. Carabantes Spain	8	72 0.6×	211 1.9×	97 1.2×	63 0.8×	9 0.1×	27	347
Erika Bågeman Sweden	8	47 0.4×	129 1.2×	66 0.8×	64 0.9×	21 0.3×	14	286
Kein-Seong Mun Malaysia	9	77 0.6×	107 1.0×	37 0.5×	96 1.3×	19 0.3×	22	259
Markéta Trnková Czechia	9	124 1.0×	127 1.2×	16 0.2×	140 1.9×	51 0.8×	18	307
Ioana Kloos France	11	41 0.3×	200 1.8×	110 1.3×	210 2.8×	106 1.6×	33	459
Anaïs Boulai France	5	64 0.5×	69 0.6×	19 0.2×	69 0.9×	23 0.3×	6	167
Paula Cabrera‐Galeana Mexico	10	155 1.3×	138 1.3×	29 0.4×	75 1.0×	36 0.5×	34	295

Countries citing papers authored by Pamela Provan

Since Specialization

Citations

This map shows the geographic impact of Pamela Provan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Provan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Provan more than expected).

Fields of papers citing papers by Pamela Provan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Provan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Provan. The network helps show where Pamela Provan may publish in the future.

Co-authorship network of co-authors of Pamela Provan

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Provan. A scholar is included among the top collaborators of Pamela Provan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Provan. Pamela Provan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Lee, Yeh Chen, Hao‐Wen Sim, Judy Kirk, et al.. (2023). Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Translational Oncology. 31. 101638–101638.

Liu, Dongli, Catherine David, Pamela Provan, et al.. (2021). Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecologic Oncology. 162(3). 720–727. 28 indexed citations

Fox, Peter, Bavanthi Balakrishnar, Rosemary L. Balleine, et al.. (2019). Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?. The Breast. 46. 52–57. 9 indexed citations

Soon, Patsy S., Pamela Provan, Edward Kim, et al.. (2017). Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Clinical & Experimental Metastasis. 35(1-2). 3–13. 13 indexed citations

Fox, Peter, Rosemary L. Balleine, Bo Gao, et al.. (2016). Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. Clinical Cancer Research. 22(13). 3164–3171. 64 indexed citations

Janssen, Anna, Tracy Robinson, Pamela Provan, & Tim Shaw. (2016). The Sydney West Knowledge Portal: Evaluating the Growth of a Knowledge Portal to Support Translational Research. Journal of Medical Internet Research. 18(6). e170–e170. 1 indexed citations

Fox, Peter, Bavanthi Balakrishnar, Rosemary L. Balleine, et al.. (2016). Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?. Journal of Clinical Oncology. 34(15_suppl). 536–536. 1 indexed citations

Robinson, Tracy, Anna Janssen, Paul R. Harnett, et al.. (2016). Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science. Australian Health Review. 41(3). 291–296. 15 indexed citations

Pathmanathan, Nirmala, Rosemary L. Balleine, Upali W Jayasinghe, et al.. (2014). The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. Journal of Clinical Pathology. 67(3). 222–228. 41 indexed citations

10.

Provan, Pamela, Karen Byth, Robert L. Walker, et al.. (2013). Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology. 45(7). 629–636. 7 indexed citations

11.

Fox, Peter, Bo Gao, Bavanthi Balakrishnar, et al.. (2013). Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. Journal of Clinical Oncology. 31(15_suppl). 543–543. 2 indexed citations

12.

Pathmanathan, Nirmala, Pamela Provan, Hema Mahajan, et al.. (2012). Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. The Breast. 21(6). 724–729. 22 indexed citations

13.

Balleine, Rosemary L., Pamela Provan, Gulietta M. Pupo, et al.. (2010). Familial concordance of breast cancer pathology as an indicator of genotype in multiple‐case families. Genes Chromosomes and Cancer. 49(12). 1082–1094. 6 indexed citations

14.

Pathmanathan, Nirmala, Pamela Provan, J. Milliken, et al.. (2010). Diagnostic evaluation of papillary lesions of the breast on core biopsy. Modern Pathology. 23(7). 1021–1028. 20 indexed citations

15.

Pathmanathan, Nirmala, Elizabeth Salisbury, Pamela Provan, et al.. (2009). A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breast. Pathology. 42(1). 28–36. 1 indexed citations

16.

Ringland, Clare, Adrienne Morey, Andrew M. Hanby, et al.. (2008). Poor-Prognosis Estrogen Receptor–Positive Breast Cancer Identified by Histopathologic Subclassification. Clinical Cancer Research. 14(20). 6625–6633. 10 indexed citations

17.

Loughrey, Maurice B., Pamela Provan, Karen Byth, & Rosemary L. Balleine. (2008). Histopathological features of ‘BRCAX’ familial breast cancers in the kConFab resource. Pathology. 40(4). 352–358. 7 indexed citations

18.

Balleine, Rosemary L., Rajmohan Murali, A. Michael Bilous, et al.. (2006). Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology. 49(5). 523–532. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact